Spotlight on levetiracetam in epilepsy

Area of Science:

• Pharmacology and Neurology
• Drug Discovery and Development

Background:

• Levetiracetam is a second-generation antiepileptic drug (AED) with established efficacy.
• It is approved for adjunctive treatment of partial-onset seizures, myoclonic seizures in juvenile myoclonic epilepsy, and generalized tonic-clonic seizures in idiopathic generalized epilepsy.

Purpose of the Study:

• To review the efficacy, mechanisms of action, pharmacokinetics, and safety of levetiracetam.
• To highlight its established role in epilepsy management.

Main Methods:

• Review of randomized, double-blind, controlled, multicentre trials.
• Analysis of pharmacokinetic and safety data from clinical studies.

Main Results:

• Levetiracetam demonstrated significant seizure frequency reduction compared to placebo in refractory partial-onset seizures.
• Monotherapy was noninferior to carbamazepine for newly diagnosed partial-onset seizures.
• Improvements in health-related quality of life were observed.
• Adverse events were generally mild to moderate and similar in proportion to placebo.

Conclusions:

• Levetiracetam possesses unique mechanisms of action, including binding to synaptic vesicle protein 2A.
• Its pharmacokinetic profile is favorable, with minimal drug interactions.
• Levetiracetam is an effective and generally well-tolerated AED for specific epilepsy types, though behavioral effects may occur.